Logo-bi
Bioimpacts. 2016;6(3): 119-124.
doi: 10.15171/bi.2016.18
PMID: 27853675
PMCID: PMC5108984
Scopus ID: 85003976973
  Abstract View: 2388
  PDF Download: 1821
  Full Text View: 2898

Original Research

The effects of valsartan on renal glutathione peroxidase expression in alleviation of cyclosporine nephrotoxicity in rats

Sina Raeisi 1,2,3, Amir Ghorbanihaghjo 1*, Hassan Argani 4, Siavoush Dastmalchi 5, Babollah Ghasemi 6, Teimour Ghazizadeh 2, Nadereh Rashtchizadeh 5, Mehran Mesgari Abbasi 1, Nasrin Bargahi 5, Mahboob Nemati 7, Ali Mota 2, Amir Mansour Vatankhah 1

1 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
3 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
4 Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
6 Division of Clinical Laboratory, Tabriz Children’s Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
7 Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
*Corresponding Author: Email: ghorbaniamir@hotmail.com

Abstract

Introduction: Nephrotoxicity as a side effect caused by the immunosuppressive drug, cyclosporine-A (CsA), can be a major problem in transplant medicine. Oxidative stress may play an important role in the CsA-induced nephrotoxicity. It has been shown that the antihypertensive drug, valsartan (Val), has also renoprotective effects but, its molecular mechanism is largely unknown. In the present study, it was aimed to evaluate the Val effect in the alleviation of CsA nephrotoxicity via probable renal glutathione peroxidase (GPx) upregulation and oxidative stress decrease.
Methods: Thirty-two Sprague-Dawley rats were divided into four groups based on CsA and/or Val administration: group A (Control, 1 mL/kg/day of olive oil as vehicle), group B (CsA, 30 mg/kg/day), group C (CsA+Val, 30+30 mg/kg/day), and group D (Val, 30 mg/kg/day). After the administration period (six weeks), renal GPx expression was evaluated by real-time polymerase chain reaction (PCR). Plasma levels of GPx and 8-Hydroxydeoxyguanosine (8-OHdG) were measured by enzyme-linked immunosorbent assay (ELISA). Malondialdehyde (MDA) and protein carbonyl groups (PCG) were measured by spectrophotometer. Plasma levels of urea and creatinine were measured by an autoanalyzer.
Results: CsA treatment led to the decrease in renal expression and plasma levels of GPx in comparison to other study groups. Rats received CsA were detected to have significantly (p<0.05) higher plasma 8-OHdG, MDA, PCG, urea, and creatinine levels in comparison to other groups. Plasma urea and creatinine levels were negatively correlated with renal GPx expression and positively correlated with the oxidative stress markers.
Conclusion: Administration of Val may result in attenuating the nephrotoxic side effect of CsA via probable renal GPx upregulation, and subsequently oxidative stress decrease.

First Name
Last Name
Email Address
Comments
Security code


Abstract View: 2389

Your browser does not support the canvas element.


PDF Download: 1821

Your browser does not support the canvas element.


Full Text View: 2898

Your browser does not support the canvas element.